Our Team.
OUR TEAM
Our core pipeline products target the treatment and prevention in disease and infection in women’s health. Our intellectual property includes a strong patent-protected drug pipeline. Our teams in research, board of directors, management and scientific advisors are world class.
Executive Team
Craig Travis, MD -
CEO (Interim) and President
Although Dr. Travis had been a practicing board certified emergency physician for more than forty years, the six years which he spent in Negril Jamaica (1988-1994) became the most consequential of his life
with his need to reconcile the widespread use of cannabis in a highly
promiscuous population and the astonishingly low prevalence of HIV.
This need led him on a scientific venture (together with other
collaborative researchers) to establish that a non-psychoactive
derivative of tetrahydrocannabinol (THC), effectively increases the
barrier function of vaginal tissue that can provide protection against HIV transmission, and provide an alternative to the hormonal
treatment of the genitourinary syndrome of menopause (GSM). His dogged determination resulted in a patent for a compound ready to
advance through the development pipeline for human use.
with his need to reconcile the widespread use of cannabis in a highly
promiscuous population and the astonishingly low prevalence of HIV.
This need led him on a scientific venture (together with other
collaborative researchers) to establish that a non-psychoactive
derivative of tetrahydrocannabinol (THC), effectively increases the
barrier function of vaginal tissue that can provide protection against HIV transmission, and provide an alternative to the hormonal
treatment of the genitourinary syndrome of menopause (GSM). His dogged determination resulted in a patent for a compound ready to
advance through the development pipeline for human use.
Wendy J. Weiser -
Chief Operating Officer
Wendy Weiser, with expertise in starting and running small and large organizations of physicians and scientists serves as the Chief Operating Officer
David Fater, CPA -
Chief Financial Officer
In addition to serving as Immugen's Chief Financial Officer, David founded and has served as Chief Executive Officer of ALDA & Associates International, a management services firm focused on life
sciences and healthcare since its inception in January 1993.
sciences and healthcare since its inception in January 1993.
Latresia Wilson, M.D., Ph.D -
Chief Scientific Officer
In addition to serving as Immugen's Chief Scientific Officer, Dr. Wilson is a Fellow of the American College of Emergency Physicians as well as a certified medical marijuana prescriber with an NIH
research background.
research background.
Tamara Gholson Bavendam, M.D. -
Executive VP, Strategic Planning
Tamara Bavendam, MD, MS has clinical expertise in female pelvic floor disorders including GSM, was a Senior Medical Director at Pfizer, Inc for 10 years and a Senior Scientific Officer in the National Institutes of Diabetes and Digestive and Kidney Diseases for over 8 years serves as Senior Vice President Strategic Planning.
Bill W. Massey, Ph.D. - Executive VP, Regulatory Affairs
Dr. Massey is a neuropharmacologist, pharmacogeneticist, life sciences professional, senior executive and entrepreneur. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences and subsequently was an investigator at the Pritzker School of Medicine’s Drug Abuse Research Center at The University of Chicago.